|
2023-02-27 |
2022-11-28 |
S
Sale
|
Non-Executive Director
Large shareholder
|
87,041
+12.5%
108.87
US$3,861,741
|
87,041
+12.5%
|
108.87
|
US$3,861,741
|
|
|
2022-08-17 |
2022-08-15 |
B
Purchase
|
Large shareholder
|
90,660
+27.6%
116.04
US$1,393,225
|
90,660
+27.6%
|
116.04
|
US$1,393,225
|
|
|
2022-08-17 |
2022-08-15 |
B
Purchase
|
Large shareholder
|
29,604
+3.0%
45.23
US$1,121,201
|
29,604
+3.0%
|
45.23
|
US$1,121,201
|
|
|
2022-08-17 |
2022-08-15 |
B
Purchase
|
Large shareholder
|
133,333
+3.3%
30.00
US$3,999,990
|
133,333
+3.3%
|
30.00
|
US$3,999,990
|
|
|
2022-08-15 |
2022-08-11 |
B
Purchase
|
Large shareholder
|
83,000
+2.0%
30.00
US$2,490,000
|
83,000
+2.0%
|
30.00
|
US$2,490,000
|
|
|
2022-08-15 |
2022-08-11 |
B
Purchase
|
Large shareholder
|
500,000
+9.0%
30.00
US$15,000,000
|
500,000
+9.0%
|
30.00
|
US$15,000,000
|
|
|
2022-08-15 |
2022-08-11 |
B
Purchase
|
Large shareholder
|
83,000
+2.0%
30.00
US$2,490,000
|
83,000
+2.0%
|
30.00
|
US$2,490,000
|
|
|
2022-08-15 |
2022-08-11 |
B
Purchase
|
Non-Executive Director
Large shareholder
|
6,000
+inf%
30.00
US$180,000
|
6,000
+inf%
|
30.00
|
US$180,000
|
|
|
2022-08-15 |
2022-08-11 |
B
Purchase
|
Non-Executive Director
Large shareholder
|
500,000
+9.0%
30.00
US$15,000,000
|
500,000
+9.0%
|
30.00
|
US$15,000,000
|
|
|
2023-02-27 |
2022-06-10 |
S
Sale
|
Chief Medical Officer
Officer
|
6
-0.2%
15.21
US$91
|
6
-0.2%
|
15.21
|
US$91
|
|
|
2022-01-13 |
2022-01-11 |
B
Purchase
|
EVP CFO & Chief BD Officer
Officer
|
100
+inf%
16.00
US$1,600
|
100
+inf%
|
16.00
|
US$1,600
|
|
|
2022-01-13 |
2022-01-11 |
B
Purchase
|
Large shareholder
|
325,000
+6.2%
16.00
US$5,200,000
|
325,000
+6.2%
|
16.00
|
US$5,200,000
|
|
|
2022-01-13 |
2022-01-11 |
B
Purchase
|
Non-Executive Director
Large shareholder
|
325,000
+6.2%
16.00
US$5,200,000
|
325,000
+6.2%
|
16.00
|
US$5,200,000
|
|
|
2022-01-13 |
2022-01-11 |
B
Purchase
|
Large shareholder
|
220,000
+5.7%
16.00
US$3,520,000
|
220,000
+5.7%
|
16.00
|
US$3,520,000
|
|
|
2022-01-13 |
2022-01-11 |
B
Purchase
|
Large shareholder
|
312,500
+170.0%
16.00
US$5,000,000
|
312,500
+170.0%
|
16.00
|
US$5,000,000
|
|
|
2022-01-13 |
2022-01-11 |
B
Purchase
|
Large shareholder
|
157,500
+4.3%
16.00
US$2,520,000
|
157,500
+4.3%
|
16.00
|
US$2,520,000
|
|
|
2022-01-13 |
2022-01-11 |
B
Purchase
|
Large shareholder
|
1,700,000
+70.1%
16.00
US$27,200,000
|
1,700,000
+70.1%
|
16.00
|
US$27,200,000
|
|
|
2022-01-13 |
2022-01-11 |
B
Purchase
|
Chief Executive Officer
Executive Director
|
12,500
+inf%
16.00
US$200,000
|
12,500
+inf%
|
16.00
|
US$200,000
|
|
|
2022-01-13 |
2022-01-11 |
B
Purchase
|
Chief Operating Officer
Officer
|
1,500
+inf%
16.00
US$24,000
|
1,500
+inf%
|
16.00
|
US$24,000
|
|
|
2022-01-13 |
2022-01-11 |
B
Purchase
|
Chief Operating Officer
Officer
|
750
+0.6%
16.00
US$12,000
|
750
+0.6%
|
16.00
|
US$12,000
|
|
|
2022-01-13 |
2022-01-11 |
B
Purchase
|
EVP Clinical Development
Officer
|
100
+inf%
16.00
US$1,600
|
100
+inf%
|
16.00
|
US$1,600
|
|
|
2022-01-13 |
2022-01-11 |
B
Purchase
|
EVP Clinical Development
Officer
|
2,500
+inf%
16.00
US$40,000
|
2,500
+inf%
|
16.00
|
US$40,000
|
|
|
2022-01-13 |
2022-01-11 |
B
Purchase
|
Large shareholder
|
1,700,000
+70.1%
16.00
US$27,200,000
|
1,700,000
+70.1%
|
16.00
|
US$27,200,000
|
|